Navigation Links
MannKind Corporation Reports Second Quarter Financial Results
Date:8/11/2008

ry promising. As Al Mann said, this is an exciting time, full of promise for the future."

Conference Call

MannKind management will host a conference call to discuss these results today at 5:00 p.m. Eastern Time. To participate in the call please dial (888) 677-5721 or (210) 839-8507. To listen to the call via the Internet please visit http://www.mannkindcorp.com. The web site replay will be available for fourteen days. A telephone replay will be accessible for approximately 14 days following completion of the call by dialing (800) 219-6350 or (402) 220-3904 and entering conference number 4423748.

Presenting from the Company will be:

-- Chairman and Chief Executive Officer Alfred Mann

-- President and Chief Operating Officer Hakan Edstrom

-- Corporate Vice President and Chief Financial Officer Matthew Pfeffer

-- Corporate Vice President and Chief Scientific Officer Peter Richardson

About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. Its lead product, the Technosphere Insulin System, is currently in Phase 3 clinical trials in the United States, Europe and Latin America to study its safety and efficacy in the treatment of diabetes. For more information on MannKind Corporation and its technology, visit http://www.mannkindcorp.com.

Forward-Looking Statements

This press release contains forward-looking statements, including statements related to MannKind's expected G&A expenses, clinical trials, product candidates
'/>"/>

SOURCE MannKind Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related biology technology :

1. MannKind Corporation to Hold Second Quarter Financial Results Conference Call on August 11, 2008
2. MannKind to Present at Upcoming Conferences
3. MannKind Corporation Reports First Quarter Financial Results
4. MannKind to Present at the Morgan Stanley Healthcare Conference
5. MannKind Corporation to Hold First Quarter Financial Results Conference Call on May 5, 2008
6. Matthew J. Pfeffer Joins MannKind as Corporate Vice President and Chief Financial Officer
7. MannKind Corporation Response to Recent Market Events
8. MannKind Corporation to Hold Fourth Quarter Financial Results Conference Call on March 4, 2008
9. MannKind to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
10. MannKind to Present at the Wachovia 2008 Healthcare Conference
11. MannKind to Present at the Piper Jaffray Healthcare Conference

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/5/2009)...Newswire-FirstCall/ -- Wound Management Technologi...red into a Letter of Intent to purchase all health..., Inc. (OTC Bulletin Board: VHGI). The deal provid..., 4,000,000 shares of WNDM and a royalty agreement...echnology being acquired from VHGI. WNDM closed ...
(Date:11/5/2009)...v. 5 /PRNewswire-Asia-FirstCall/ -- BMP Sunstone,C... "Company") today announced,that the Company plans...n,Monday, November 9, 2009, after the market close...all at 5:00 pm ET on November 9, 2009,to discuss t...he call by,dialing 1-888-713-4211 or 1-617-213-486...
(Date:11/4/2009)...nar, which will be presented on November 19 and is...chemistry processing, will deal with the applicati...eso and micro scale flow chemistry equipment. Pro...n recognized with several prestigious prizes and a...n Prize. , Columbia, MD (...
(Date:11/4/2009).... 4 Zyngenia, Inc., a privately he...ion antibody drug development, today announced tha...rom New Enterprise Associates (NEA), one of the wo...ill be used to create novel, multi-specific antibo...cal targets with a single agent. The company will ...
Breaking Biology Technology:OTCBB-WNDM Announces LOI to Acquire VHGI Assets for $10 Million Cash/Stock 2OTCBB-WNDM Announces LOI to Acquire VHGI Assets for $10 Million Cash/Stock 3BMP Sunstone to Report Third Quarter 2009 Financial Results 2Professor Steven Ley of University of Cambridge will Present Free Webinar, 'Application of the ReactIR Flow Cell to Continuous Processing Technology' 2Professor Steven Ley of University of Cambridge will Present Free Webinar, 'Application of the ReactIR Flow Cell to Continuous Processing Technology' 3Zyngenia, Inc. Raises $10 Million in Series A Funding 2Zyngenia, Inc. Raises $10 Million in Series A Funding 3Zyngenia, Inc. Raises $10 Million in Series A Funding 4
...eeds to be used to support the achievement of seve...ilestones of Acasti Pharma, LAVAL, QC, Oct. 9 /PR...ptune Technologies & Bioressources Inc. ("Neptune"...he Company successfully completed as of,October 8,...le debentures,for gross proceeds of $2,750,000., ...
... Management Solution Will Help Commonwealth Care A...FORD, Mass., Oct. 9 Casenet, Inc., a provider of,...ay announced that,Commonwealth Care Alliance, a no...enet,s case management solution to more effectivel...osters collaboration and communication,between dir...
...any Announces Corporate Restructuring to Focus on ... and M&A, SAN DIEGO, Oct. 8 Nventa Biopharmaceut... innovative therapeutics for,the treatment of vira...on,its ongoing development programs. The company a...structuring that will extend the company,s financi...
Other Biology Technology:Neptune Technologies successfully completes $2.75 million private placement with 10% management participation 2Neptune Technologies successfully completes $2.75 million private placement with 10% management participation 3Neptune Technologies successfully completes $2.75 million private placement with 10% management participation 4Commonwealth Care Alliance Selects Casenet To Unify Patient Information and Improve Care for Massachusetts Members 2Commonwealth Care Alliance Selects Casenet To Unify Patient Information and Improve Care for Massachusetts Members 3Nventa Provides Corporate Update and Advancement Plans for HspE7, Hsp 6/11 and Poly-ICR 2Nventa Provides Corporate Update and Advancement Plans for HspE7, Hsp 6/11 and Poly-ICR 3Nventa Provides Corporate Update and Advancement Plans for HspE7, Hsp 6/11 and Poly-ICR 4Nventa Provides Corporate Update and Advancement Plans for HspE7, Hsp 6/11 and Poly-ICR 5Nventa Provides Corporate Update and Advancement Plans for HspE7, Hsp 6/11 and Poly-ICR 6Nventa Provides Corporate Update and Advancement Plans for HspE7, Hsp 6/11 and Poly-ICR 7Nventa Provides Corporate Update and Advancement Plans for HspE7, Hsp 6/11 and Poly-ICR 8
(Date:11/4/2009)...natural science) , United States Using Less Wa...oday than it did 35 years ago, despite a 30 percen...artly attributable to alternative cooling methods ...ems. According to the latest USGS water use report...es goes to cooling thermoelectric power plants. Ir...
(Date:11/4/2009)...y that deciphered the DNA codes, or genomes, of th...as joined The Genome 10K Project, an international...equences on 10,000 species of animals for conducti...an not be achieved. , Participating in The Genom...he Nov. 5, 2009 issue of the Journal of Heredity ...
(Date:11/4/2009)...., Oct. 20 DigitalPersona, Inc., a... solutions, today announced that WAND Corporation,...e for quick-service restaurants, has integrated Di... Classic POS solutions. WAND,s quick-service custo...ashier accountability and deter unauthorized manag...
Breaking Biology News(10 mins):USGS science picks 2USGS science picks 3USGS science picks 4USGS science picks 5USGS science picks 6USGS science picks 7Singapore scientists join international study of 10,000 vertebrates' genomes 2WAND Point-of-Sale Solutions Integrate U.are.U(R) Fingerprint Biometrics From DigitalPersona for Quick-Service Restaurants 2WAND Point-of-Sale Solutions Integrate U.are.U(R) Fingerprint Biometrics From DigitalPersona for Quick-Service Restaurants 3Inhibition of NF kappa B a key inflammatory protein reduced radiation toxicity in zebrafish 55919 1Inhibition of NF kappa B a key inflammatory protein reduced radiation toxicity in zebrafish 55919 2SAGE to publish leading international headache journal Cephalalgia 55917 1SAGE to publish leading international headache journal Cephalalgia 55917 2Stuy in NEJM 3A New therapy prevents heart failure 55915 1Stuy in NEJM 3A New therapy prevents heart failure 55915 2
...e work of Forsyth scientist Peter Jezewski, DDS, P...ation of protein regions (,modules,) within ancien... of certain birth disorders. Tracing the history o...sx gene family over the past 600 million years has... origin of the human mouth. , Dr. Jezewski has p...
...io College-age football players who gain weight t... be setting themselves up for diabetes and heart d...rly half of a sample of collegiate offensive and d...for the study had metabolic syndrome. This means t... that indicate a person has higher chances of deve...
...kthroughs in the treatment of many common diseases...d by harnessing a powerful scientific approach cal...ts from across Europe. In a Science Policy Briefin...n, the scientists provide a detailed strategy for ...arch over the coming years. , Systems biology is ...
Other Biology News:Scientists uncover evolutionary keys to common birth disorders 2Athletes not spared from health risks of metabolic syndrome 2Athletes not spared from health risks of metabolic syndrome 3Key to future medical breakthroughs is systems biology, say leading European scientists 2Key to future medical breakthroughs is systems biology, say leading European scientists 3
Mouse Anti-IFN-alpha2 Monoclonal Antibody, Fluorescein isothiocyanate (FITC) Conjugated, Clone 225.C from eBioscience
Mouse Anti-alpha Sodium Potassium ATPase Monoclonal Antibody, Unconjugated, Clone M7-PB-E9 from Abcam
Rabbit Anti-Human SP2 Polyclonal Antibody, Unconjugated from Atlas Antibodies
Rabbit Anti-Asparagine synthetase Monoclonal Antibody, Unconjugated, Clone EP282Y from Abcam
Biology Products: